Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zoster in Vulnerable Population Receiving ImmunOmodulaNt Therapies

NCT07534007 · clinicaltrials.gov ↗

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

RZV Vaccine (Shingrix ®)

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia